NNVC NanoViricides Inc
Company Analysis
Latest News
NanoViricides Secures $3.8 Million in Registered Direct Offering
NanoViricides, Inc. entered a securities purchase agreement with a single institutional investor on July 24, 2026. The registered direct offering expects to...
🟢 NanoViricides is trading 5.2% up today, rebounding from an earlier drop with no clear catalyst identified
NanoViricides is trading at $1.56 (5.2% up) in after-hours trading, rebounding from a 10.5% drop earlier on July 24 to $1.37 with no clear news catalyst. *...
🔴 NanoViricides is trading 10.5% down today with no clear catalyst identified
NanoViricides is trading 10.5% lower at $1.37 following a sharp drop from its July 23 close of $1.53, despite a lack of fresh company-specific news, earnings,...
🔴 NanoViricides is trading 8.6% down today with no clear company-specific catalyst identified
NanoViricides is trading 8.59% down at $1.40 in pre-market with no clear company-specific catalyst identified after a sharp move lower from its $1.53 close on...
🔴 NanoViricides is trading 5% down today on profit-taking and biotech sector weakness
NanoViricides is trading 5% down today at $1.66 as the stock faces profit-taking following a recent rally and broader pressure on the biotechnology sector. •...
🔴 NanoViricides is trading 5.28% down today amid broader biotech weakness and risk-off pressure
NanoViricides is trading at $1.68 (-5.28%) following a sharp move lower in early trading despite a lack of company-specific news, filings, or analyst...
🟢 NanoViricides is trading 5% up today on speculative interest
NanoViricides is trading 5% up at $1.81, extending a volatile recent upswing despite a lack of fresh company-specific headlines, filings, or analyst...
🟢 NanoViricides is trading 10.0% up
NanoViricides is trading at $1.81, up 10.0% from a comparison close of $1.65 during regular trading. This is a price-action follow-up, so a separate catalyst...
🟢 NanoViricides is trading 5.2% up today, extending a multi-day rally despite a weak biotech tape
NanoViricides is trading 5.2% up at $1.74 today, extending a strong multi-day rally that began earlier in July while moving independently of a broader decline...
🟢 NanoViricides is trading 11.1% up
NanoViricides is trading at $1.68, up 11.1% from a comparison close of $1.51 during regular trading. This is a price-action follow-up, so a separate catalyst...
🟢 NanoViricides soars 6% on Ebola trial approval in DRC and bullish Noble Capital coverage
NanoViricides is trading at $1.60 (+5.96%), gaining momentum after receiving approval for a Phase II Ebola trial and continued positive sentiment from analyst...
🔴 NanoViricides is trading 5.2% down today on profit-taking following a sharp multi-day rally
NanoViricides is trading 5.2% down today at $1.53 as the stock undergoes consolidation following a significant multi-day run. • The recent momentum was fueled...
🟢 NanoViricides is trading 5.4% up today on Outperform rating and NV-387 clinical progress
NanoViricides is trading at $1.63 (up 5.4%), extending yesterday’s jump after Noble Capital Markets initiated coverage on the stock with an Outperform rating...
🟢 NNVC is trading 6% up today on "Outperform" analyst rating and NV-387 clinical progress
NanoViricides (NNVC) is trading at $1.55 (up 6%) after Noble Capital Markets initiated coverage with an "Outperform" rating and a $6.00 price target. The...
NanoViricides advances oral Ebola drug to Phase II, targeting DRC outbreak
NanoViricides, Inc. announced on July 6, 2026, that it is advancing its broad-spectrum antiviral drug, NV-387, toward a Phase II clinical trial in the...
🔴 NNVC is trading 8.2% down today, extending a pullback after a strong multi-month run
NNVC is trading 8.2% down at $1.24 in pre-market, extending a mild pullback after a strong multi-month run and recent high volatility. • No fresh...
NanoViricides Gets an FDA Gold Star for Its Measles Drug — But Can a Seven-Person Company Actually Deliver a $100M-Plus Payday?
Shares of NanoViricides slid 11.2% to $1.22 in pre-market trading on June 30, pulling back sharply after a week-long rally triggered by back-to-back regulatory...
🔴 NNVC is trading 11.2% down today as traders reassess rally following FDA rare pediatric designation
NNVC is trading 11.2% down at $1.22 in pre-market, pulling back after a sharp recent advance following news that the FDA granted Rare Pediatric Disease Drug...
NanoViricides Wins FDA Pediatric Status for Measles Drug, Eligible for $100M Voucher
NanoViricides Inc. (NNVC) received U.S. Food and Drug Administration (FDA) Rare Pediatric Disease Drug (RPDD) designation for its antiviral drug NV-387. This...